Literature DB >> 23227009

Contribution of oxidative stress to endothelial dysfunction in hypertension.

Bruno R Silva1, Laena Pernomian, Lusiane M Bendhack.   

Abstract

Endothelial dysfunction is the hallmark of hypertension, which is a multifactorial disorder. In the cardiovascular system reactive oxygen species play a pivotal role in controlling the endothelial function and vascular tone. Physiologically, the endothelium-derived relaxing factors (EDRFs) and endothelium-derived contractile factors (EDCFs) that have functions on the vascular smooth muscle cells. The relaxation induced by the EDRFs nitric oxide (NO), prostacyclin, and the endothelium-derived hyperpolarization factor (EDHF) could be impaired in hypertension. The impaired ability of endothelial cells to release NO along with enhanced EDCFs production has been described to contribute to the endothelium dysfunction, which appears to lead to several cardiovascular diseases. The present review discusses the role of oxidative stress, vascular endothelium, and vascular tone control by EDRFs, mainly NO, and EDCFs in different models of experimental hypertension.

Entities:  

Keywords:  NO availability; endothelial dysfunction; hypertension; oxidative stress; vascular contraction; vascular relaxation

Year:  2012        PMID: 23227009      PMCID: PMC3514688          DOI: 10.3389/fphys.2012.00441

Source DB:  PubMed          Journal:  Front Physiol        ISSN: 1664-042X            Impact factor:   4.566


Hypertension is a multifactorial disorder that involves many mechanisms leading to risk factors for cardiovascular diseases. Endothelial dysfunction is defined as the imbalance between the production and bioavailability of endothelium-derived relaxing factors (EDRFs) and endothelium-derived contractile factors (EDCFs), associated with increased bioavailability of oxygen reactive species (ROS) and decreased antioxidant capacity characterized as oxidative stress. In this review we will discuss the involvement of oxidative stress and vascular endothelium as well as the importance of vascular tone control, relaxation, and contraction in hypertension. NO is an important mediator released by endothelial cells. It is produced by NO synthases (NOS), which convert L-arginine and molecular oxygen to L-citrulline and NO, using such co-factors as tetrahydrobiopterin (BH4), flavin-adenine-dinucleotide, flavin-mononucleotide, and nicotinamide-adenine-dinucleotide-phosphate (Thomas et al., 2008). The activity of NOS is regulated by substrate, cofactor availability, and electron transfer rate. The regulating factors such as arginine (Gornik and Creager, 2004) and BH4 (Bevers et al., 2006) can be affected by ROS that can lead to dysfunctional eNOS. As summarized in the Figure 1, in pathological states involving oxidative stress such as hypertension NOS could be uncoupled (Schulz et al., 2008). L-arginine is the substrate for both enzymes, NOS and arginase (Tousoulis et al., 2002). Zhang et al. (2004) showed that the activity of arginase in the endothelial cells of coronary arterioles is increased in hypertension, which impairs the NO-mediated dilation. Similarly, as reported by Chandra et al. (2012) peroxynitrite (ONOO−) and hydrogen peroxide (H2O2) increase arginase activity/expression in the endothelial cells. This should lead to NOS uncoupling with reduced NO production and augmented superoxide anion (O−2) production. As shown by Romero et al. (2008), increased arginase activity in diabetes contributes to vascular endothelium dysfunction by decreasing L-arginine availability to NOS.
Figure 1

Sources of reactive oxygen species (ROS) and proposed mechanisms for their contribution to EDRFs and EDCFs releasing involved in the control of vascular tone in isolated vessels from normotensive (A) and hypertensive (B) animals.

Sources of reactive oxygen species (ROS) and proposed mechanisms for their contribution to EDRFs and EDCFs releasing involved in the control of vascular tone in isolated vessels from normotensive (A) and hypertensive (B) animals. Endothelial dysfunction culminates in impaired endothelium-dependent relaxation due to decreased vascular NO bioavailability caused by ROS consumption. The result is ONOO− formation, lower NOS protein expression, or lack of substrate or co-factor for NOS (Crimi et al., 2007). The eNOS phosphorylation state can alter its activity; i.e., Akt-dependent phosphorylation at Ser1177 (human) or Ser1179 (bovine) activates eNOS (Fulton et al., 1999), while phosphorylation at Thr495 (human) or Thr497 (bovine) decreases its activation (Bouloumié et al., 1997). H2O2 initially raises eNOS Ser1179 phosphorylation and activity, in parallel with transient Akt activation (Hu et al., 2008). In vivo measurements of NO and H2O2 in the mesenteric arteries of spontaneously hypertensive rats (SHR) revealed higher baseline NO and H2O2 concentrations than normotensive rats (Zhou et al., 2008). It is known that in resistance arteries more than in conduit vessels, EDHF is an important control of vascular tone. H2O2 has been shown to be a component of EDHF in several vascular beds (Meurer et al., 2005; Shimokawa, 2010; Prysyazhna et al., 2012). Peroxynitrite can also activate eNOS by increasing basal and agonist-stimulated Ser1179 phosphorylation, although it reduces NO bioavailability and elevates O−2 production (Zou et al., 2002a). eNOS exposure to oxidants like ONOO− causes increased enzymatic uncoupling and O−2 generation in diabetes that contributes to endothelial cell oxidant stress (Zou et al., 2002b). Increased formation of ONOO− can inhibit prostacyclin synthase (PGIS) (Wu and Liou, 2005) and impairs K+ channel activation (Gutterman et al., 2005). Increased ROS bioavailability, decreased antioxidant capacity, or both occur in many models of hypertension such as SHR (Suzuki et al., 1995), Dahl salt-sensitive (Swei et al., 1997), AngII-infused rats (Laursen et al., 1997), renal hypertensive 2K-1C (Rodrigues et al., 2008), and human hypertension (Vaziri, 2004). In endothelial cells, the ROS producers are NADPH oxidase (Rajagopalan et al., 1996), xanthine oxidase (Phan et al., 1989), uncoupled NOS (Satoh et al., 2005), cyclooxygenase (COX) (Tang et al., 2007), and mitochondria (Callera et al., 2006). The DOCA-salt model present augmented oxidative stress caused by increased NADPH oxidase activity, which accounts for enhanced O−2 production (Beswick et al., 2001). In 2K-1C rats, the increased vascular O−2 is secondary to a protein kinase C (PKC)-mediated activation of NADPH oxidase (Heitzer et al., 1999). However, eNOS activity is reduced by phosphorylation of the Thr495 residue in the Ca2+/CaM binding domain by PKC (Mount et al., 2007). Mimicking of Thr495 dephosphorylation results in eNOS uncoupling and O−2 production rather than NO generation (Lin et al., 2003). However, whether the Thr495 eNOS phosphorylation site is more phosphorylated in hypertension or contains uncoupled eNOS remains unknown. We have investigated the vascular mechanisms involved in the vasorelaxation induced by NO donors that present potential capacity to replenish vascular NO upon reduced NO bioavailability. Most of the studies using NO donors are performed on endothelium-denuded arteries to avoid interference of endogenously produced NO (Bonaventura et al., 2004; Pereira et al., 2011). Impaired 2K-1C rat aorta relaxation is endothelium-dependent (Callera et al., 2004) or endothelium-independent (Bonaventura et al., 2005). Vitamin-C normalized the impaired relaxation induced by a NO donor in 2K-1C rat aorta that shows the increased ROS production in the vascular smooth muscle cells (Rodrigues et al., 2008). Interestingly, the endothelium can contribute to the vasorelaxation induced by sodium nitroprusside (SNP) via NOS activation (Bonaventura et al., 2008). The endothelium negatively modulates the vasorelaxation induced by the complex (TERPY) in the rat aorta. BH4 supplementation reverses the effect of uncoupled NOS induced by TERPY (Bonaventura et al., 2009). The altered function of endothelial cells leads to enhanced contraction (Endemann and Schiffrin, 2004). The EDCFs released under different stimuli include ET-1 (Taddei et al., 2003), some prostanoids, and ROS (Tang and Vanhoutte, 2009). ET-1 activates ETA and ETB receptors. ETA receptors are expressed on smooth muscle cells and promote contraction. ETB receptors are located on endothelial and smooth muscle cells, with opposite effects. Smooth muscle ETB activation evokes contraction, whereas endothelial ETB activation induces relaxation (Taddei et al., 2003). The imbalance in the expression of receptors or increased ET-1 production can contribute to hypertension. Hypertension associated with elevated levels of AngII leads to high vascular ET-1 production (Dohi et al., 1992) as well as ROS originated from NADPH oxidase (Touyz et al., 2002). Both factors are related to larger contractility in hypertensive rat resistance arteries. The SHR aorta exhibits a characteristic endothelial dysfunction that is not due to decreased EDRF release, but it is the result of simultaneous EDCF release. Indomethacin, a non-selective COX inhibitor, restores the blunted relaxation in SHR aorta to the level of normotensive (Lüscher and Vanhoutte, 1986), which suggests that this EDCF must be a product of the COX. Endothelium-dependent contraction is reported in the rat aorta, mesenteric and femoral arteries, and cerebral arterioles. It occurs in healthy animals, but EDCF release is exacerbated by hypertension. Selective COX-1 inhibitors abolish endothelium-dependent contraction in SHR aorta, while selective COX-2 inhibitors only display modest responses (Tang and Vanhoutte, 2009). Endoperoxides, PGI2, TXA2, and ROS are proposed as COX-derived EDCFs. Increased endothelial [Ca2+]i is required to evoke EDCF-mediated responses. Dysfunction in Ca2+ handling within the endothelium is important for the exacerbation of endothelium-dependent contractions in SHR aorta (Tang et al., 2007). Independent of the genesis of hypertension, specific ROS such as H2O2 modify the vascular activity of NOS and COX in concentration-dependent way (Cai et al., 2003; Gil-Longo and González-Vásquez, 2005). In hypertension, ROS are involved in augmented EDCFs and diminished EDRFs release. In the L-NAME (Qu et al., 2010) and SHR (Félétou et al., 2009) models there is increased COX-derived production of contractile prostanoids. Physiologically, PGI2 evokes vasorelaxation, whereas in aging animals or SHR it induces contraction (Vanhoutte, 2011). Inhibitors of COX (Taddei et al., 1997), NADPH oxidase (Costa et al., 2009), and xanthine oxidase (Ellis et al., 1998) or antioxidant agents such as Vitamin-C (Nishi et al., 2010) seem to diminish ROS production and EDCFs generation. In conclusion, the data presented in this work suggest that decreased NO availability along with enhanced EDCFs production contribute to the endothelium dysfunction and impaired vascular relaxation in hypertension (Figure 1). Considering the enormous progress in the area in the last years, this work addresses the function of oxidative stress on the pathogenesis of hypertension.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  55 in total

Review 1.  Endothelium-dependent contractions in hypertension: when prostacyclin becomes ugly.

Authors:  Paul M Vanhoutte
Journal:  Hypertension       Date:  2011-01-10       Impact factor: 10.190

2.  Chronic inhibition of nitric-oxide synthase potentiates endothelium-dependent contractions in the rat aorta by augmenting the expression of cyclooxygenase-2.

Authors:  Chen Qu; Susan W S Leung; Paul M Vanhoutte; Ricky Y K Man
Journal:  J Pharmacol Exp Ther       Date:  2010-05-05       Impact factor: 4.030

3.  NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat.

Authors:  R A Beswick; A M Dorrance; R Leite; R C Webb
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

4.  Ruthenium-nitrite complex as pro-drug releases NO in a tissue and enzyme-dependent way.

Authors:  Amanda de C Pereira; Peter C Ford; Roberto S da Silva; Lusiane M Bendhack
Journal:  Nitric Oxide       Date:  2011-03-31       Impact factor: 4.427

Review 5.  Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation.

Authors:  Peter F Mount; Bruce E Kemp; David A Power
Journal:  J Mol Cell Cardiol       Date:  2006-07-12       Impact factor: 5.000

6.  Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway.

Authors:  S Chandra; M J Romero; A Shatanawi; A M Alkilany; R B Caldwell; R W Caldwell
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

7.  Chronic antioxidant treatment improves arterial renovascular hypertension and oxidative stress markers in the kidney in Wistar rats.

Authors:  Erika Emy Nishi; Elizabeth Barbosa Oliveira-Sales; Cássia T Bergamaschi; Thais Galvão César Oliveira; Mirian A Boim; Ruy R Campos
Journal:  Am J Hypertens       Date:  2010-02-25       Impact factor: 2.689

8.  Antioxidant treatment with tempol and apocynin prevents endothelial dysfunction and development of renovascular hypertension.

Authors:  Cristiane A Costa; Taline A S Amaral; Lenize C R M Carvalho; Dayane T Ognibene; Andréa F E da Silva; Monique B Moss; Samuel S Valença; Roberto S de Moura; Angela C Resende
Journal:  Am J Hypertens       Date:  2009-09-24       Impact factor: 2.689

9.  Endothelium negatively modulates the vascular relaxation induced by nitric oxide donor, due to uncoupling NO synthase.

Authors:  Daniella Bonaventura; Claure N Lunardi; Gerson J Rodrigues; Mário A Neto; Juliana A Vercesi; Renata G de Lima; Roberto S da Silva; Lusiane M Bendhack
Journal:  J Inorg Biochem       Date:  2009-07-30       Impact factor: 4.155

10.  Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension.

Authors:  Oleksandra Prysyazhna; Olena Rudyk; Philip Eaton
Journal:  Nat Med       Date:  2012-01-15       Impact factor: 53.440

View more
  23 in total

1.  Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats.

Authors:  Oliul Islam; Prashanth Patil; Sumanta K Goswami; Rema Razdan; Mohammed N Inamdar; Mohammed Rizwan; Jubin Mathew; Bora Inceoglu; Kin S Stephen Lee; Sung H Hwang; Bruce D Hammock
Journal:  Cardiovasc Ther       Date:  2017-06       Impact factor: 3.023

2.  Effect of yoga on oxidative stress in elderly with grade-I hypertension: a randomized controlled study.

Authors:  Satish G Patil; Gopal B Dhanakshirur; Manjunatha R Aithala; Govindanagouda Naregal; Kusal K Das
Journal:  J Clin Diagn Res       Date:  2014-07-20

3.  In vitro Treatment with cis-[Ru(H-dcbpy-)2(Cl)(NO)] Improves the Endothelial Function in Aortic Rings with Endothelial Dysfunction.

Authors:  Jorge Camargo Oishi; Tereza Cristina Buzinnari; Cezar Rangel Pestana; Thiago Francisco De Moraes; Izabela Pereira Vatanabe; David Anderson Wink; Roberto Santana da Silva; Lusiane Maria Bendhack; Gerson Jhonatan Rodrigues
Journal:  J Pharm Pharm Sci       Date:  2015       Impact factor: 2.327

4.  Renovascular hypertension leads to DNA damage and apoptosis in bone marrow cells.

Authors:  Bianca P Campagnaro; Clarissa L Tonini; Luciano M Doche; Breno V Nogueira; Elisardo C Vasquez; Silvana S Meyrelles
Journal:  DNA Cell Biol       Date:  2013-06-20       Impact factor: 3.311

5.  In adenosine A2B knockouts acute treatment with inorganic nitrate improves glucose disposal, oxidative stress, and AMPK signaling in the liver.

Authors:  Maria Peleli; Michael Hezel; Christa Zollbrecht; A Erik G Persson; Jon O Lundberg; Eddie Weitzberg; Bertil B Fredholm; Mattias Carlström
Journal:  Front Physiol       Date:  2015-08-07       Impact factor: 4.566

6.  Oxidative Stress State Is Associated with Left Ventricular Mechanics Changes, Measured by Speckle Tracking in Essential Hypertensive Patients.

Authors:  Luis Antonio Moreno-Ruíz; David Ibarra-Quevedo; Erika Rodríguez-Martínez; Perla D Maldonado; Benito Sarabia-Ortega; José Gustavo Hernández-Martínez; Beda Espinosa-Caleti; Beatriz Mendoza-Pérez; Selva Rivas-Arancibia
Journal:  Oxid Med Cell Longev       Date:  2015-10-04       Impact factor: 6.543

7.  Sildenafil ameliorates biomarkers of genotoxicity in an experimental model of spontaneous atherosclerosis.

Authors:  Bianca P Rodrigues; Bianca P Campagnaro; Camille M Balarini; Thiago M C Pereira; Silvana S Meyrelles; Elisardo C Vasquez
Journal:  Lipids Health Dis       Date:  2013-08-28       Impact factor: 3.876

8.  Hyperglycemia induces differential change in oxidative stress at gene expression and functional levels in HUVEC and HMVEC.

Authors:  Hemang Patel; Juan Chen; Kumuda C Das; Mahendra Kavdia
Journal:  Cardiovasc Diabetol       Date:  2013-10-05       Impact factor: 9.951

9.  Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension.

Authors:  Ananda T Dias; Amanda S Cintra; Jéssica C Frossard; Zaira Palomino; Dulce E Casarini; Isabele B S Gomes; Camille M Balarini; Agata L Gava; Bianca P Campagnaro; Thiago M C Pereira; Silvana S Meyrelles; Elisardo C Vasquez
Journal:  J Transl Med       Date:  2014-09-16       Impact factor: 5.531

Review 10.  Anti-hypertensive Herbs and their Mechanisms of Action: Part I.

Authors:  Sara S Al Disi; M Akhtar Anwar; Ali H Eid
Journal:  Front Pharmacol       Date:  2016-01-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.